You just read:

Regeneron and Sanofi Receive Complete Response Letter from FDA for Sarilumab, an Investigational Treatment for Rheumatoid Arthritis

News provided by

Regeneron Pharmaceuticals, Inc.

Oct 28, 2016, 14:35 ET